MARKET

ALVO

ALVO

Alvotech
NASDAQ
4.730
-0.270
-5.40%
After Hours: 4.770 +0.04 +0.85% 18:56 12/18 EST
OPEN
5.03
PREV CLOSE
5.00
HIGH
5.05
LOW
4.670
VOLUME
900.13K
TURNOVER
--
52 WEEK HIGH
13.70
52 WEEK LOW
4.320
MARKET CAP
1.47B
P/E (TTM)
22.61
1D
5D
1M
3M
1Y
5Y
1D
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Barchart · 1d ago
Alvotech Completes $108 Million Convertible Bond Offering to Drive R&D and Biosimilar Launches
TipRanks · 1d ago
ALVOTECH SA - 2026 GUIDANCE TAKES INTO ACCOUNT IMPACT OF ANY FURTHER DELAYS IN OBTAINING CERTAIN MARKETING APPROVAL FROM U.S. FDA
Reuters · 1d ago
ALVOTECH SA - ANTICIPATES 2026 TOTAL REVENUES IN THE RANGE OF $650-$700 MILLION
Reuters · 1d ago
Alvotech to raise $100M via convertible bonds, provides 2026 forecast
Seeking Alpha · 2d ago
BRIEF-Alvotech Places $108 Mln Senior Unsecured Convertible Bonds
Reuters · 2d ago
Alvotech Raises $108 Million in Senior Unsecured Convertible Bond Offering
Reuters · 2d ago
FIS Christian Stock Fund declares annual distribution of $0.2596
Seeking Alpha · 2d ago
More
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

Webull offers Alvotech SA stock information, including NASDAQ: ALVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALVO stock methods without spending real money on the virtual paper trading platform.